A condition being an exclusion criterion in a trial does not mean the treatment is contraindicated. It frequently means the trialists wanted a cleaner population.
24 likes 16mo
Topic summary
Hepatic steatosis: what the MASH trial evidence supports
This is a generated summary. It shows the 9 most-liked posts from a topic of 84, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
c.nyberg, post #3: On the opening post — agreed on the reasoning, with one qualification. The honest answer to most questions here is that the trial population did not include the case being asked about, and that saying so is more useful than filling the gap with mechanism. Go to post
Checked the hepatic steatosis claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.
m.dumitru, post #15: Reading rather than answering, but this is the post I would point somebody at. Go to post
Registry and observational data covering excluded populations is accumulating and is weaker evidence than a trial and better than nothing.
The conclusion is tentative; the arithmetic underneath it is not.
Coming back to post #36, because the follow-up matters more than the original answer.
Bariatric surgery history: altered anatomy after surgery affects absorption. That matters for oral medications and for reconstituted solutions. Discussing specific medications and doses with a clinician familiar with bariatric surgery is prudent.
The short version is the first sentence; the rest is why.
31 likes 15mo
Adding a reference point for hepatic steatosis. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
32 likes 14mo
Post #56 is the version of this I will quote in future. One addition.
Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and cardiovascular benefit evidence is separate from the glycaemic benefit evidence.
I have said this before in a thread nobody could find, so it is worth repeating.
25 likes 14mo
Post-authorisation safety studies are the place where under-studied populations eventually appear, and they are public.
The short answer was in the first line; everything after is the working.
32 likes 13mo
Read the full topic (84 posts)
This topic was referenced in
- Hypertension improvement and when medication needs revisiting — a second datasetClinical › Comorbidities · 133 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class — setting out what I have, and where I think it stops being reliable. Something about Obstructive sleep apnoea does not reconcile and…
|
2 | 726 | 14mo | |
|
Obstructive sleep apnoea and a hard endpoint in this class
On the subject in the title: Obstructive sleep apnoea and a hard endpoint in this class Working notes rather than a conclusion. I was wrong about obstructive sleep apnoea in a thread last spring and I would…
|
+120 | 129 | 1.8k | 13mo |
|
Chronic kidney disease and the FLOW result
Posting this under the heading it deserves: Chronic kidney disease and the FLOW result Everything below is what sits behind that. Chronic kidney disease: setting out the arithmetic in full, because I have had…
|
+34 | 38 | 33k | 23mo |
|
[2026 update] Gastro-oesophageal reflux: improving or worsening?
Asking directly, because I could not find a straight answer: Gastro-oesophageal reflux: improving or worsening? Gastro-oesophageal reflux — I have the observation and I do not trust my interpretation of it,…
|
3 | 782 | 13mo | |
|
Heart failure with preserved ejection fraction: symptom endpoints
Heart failure with preserved ejection fraction: symptom endpoints — setting out what I have, and where I think it stops being reliable. Heart failure with preserved ejection keeps being re-asked here and I…
|
+19 | 23 | 311 | 12d |
Related topics — sharing the tags MASH / hepatic steatosis, PCOS, type 2 diabetes
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Semaglutide and alcohol: what is actually documented
Posting this under the heading it deserves: Semaglutide and alcohol: what is actually documented Everything below is what sits behind that. I would like to know what people here actually do about semaglutide…
|
+14 | 18 | 10k | 2d |
|
Coming back to: Renal impairment: what the labelling says about dose
Renal impairment: what the labelling says about dose — setting out what I have, and where I think it stops being reliable. Renal impairment — I have the observation and I do not trust my interpretation of it,…
|
+30 | 34 | 48k | 18mo |
|
[2026 update] Cardiovascular risk: reading the outcome trials as a set
Posting this under the heading it deserves: Cardiovascular risk: reading the outcome trials as a set Everything below is what sits behind that. I have spent a fortnight trying to pin Cardiovascular risk down…
|
+99 | 103 | 32k | 11mo |
|
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class — setting out what I have, and where I think it stops being reliable. Something about Obstructive sleep apnoea does not reconcile and…
|
2 | 726 | 14mo | |
|
Adolescents: a distinct evidence base
Adolescents: a distinct evidence base Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of adolescents is wrong? I ask because I have been…
|
3 | 11k | 9h |